PharmaEssentia Statistics
Total Valuation
PharmaEssentia has a market cap or net worth of EUR 5.21 billion. The enterprise value is 4.64 billion.
| Market Cap | 5.21B |
| Enterprise Value | 4.64B |
Important Dates
The last earnings date was Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | Aug 11, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.44% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 8.94% |
| Owned by Institutions (%) | 8.49% |
| Float | 291.08M |
Valuation Ratios
The trailing PE ratio is 38.79 and the forward PE ratio is 27.16.
| PE Ratio | 38.79 |
| Forward PE | 27.16 |
| PS Ratio | 13.49 |
| PB Ratio | 6.27 |
| P/TBV Ratio | 6.32 |
| P/FCF Ratio | 61.61 |
| P/OCF Ratio | 43.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.77, with an EV/FCF ratio of 54.89.
| EV / Earnings | 34.56 |
| EV / Sales | 12.24 |
| EV / EBITDA | 39.77 |
| EV / EBIT | 43.28 |
| EV / FCF | 54.89 |
Financial Position
The company has a current ratio of 6.83, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.83 |
| Quick Ratio | 6.45 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.30 |
| Interest Coverage | 155.89 |
Financial Efficiency
Return on equity (ROE) is 17.21% and return on invested capital (ROIC) is 8.46%.
| Return on Equity (ROE) | 17.21% |
| Return on Assets (ROA) | 7.68% |
| Return on Invested Capital (ROIC) | 8.46% |
| Return on Capital Employed (ROCE) | 12.80% |
| Revenue Per Employee | 2.95M |
| Profits Per Employee | 1.03M |
| Employee Count | 131 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | -27.46M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.79% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.79% |
| 50-Day Moving Average | 16.46 |
| 200-Day Moving Average | 17.10 |
| Relative Strength Index (RSI) | 54.39 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEssentia had revenue of EUR 386.25 million and earned 134.33 million in profits. Earnings per share was 0.36.
| Revenue | 386.25M |
| Gross Profit | 344.42M |
| Operating Income | 109.27M |
| Pretax Income | 106.87M |
| Net Income | 134.33M |
| EBITDA | 112.71M |
| EBIT | 109.27M |
| Earnings Per Share (EPS) | 0.36 |
Balance Sheet
The company has 603.40 million in cash and 24.97 million in debt, giving a net cash position of 578.43 million.
| Cash & Cash Equivalents | 603.40M |
| Total Debt | 24.97M |
| Net Cash | 578.43M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 831.76M |
| Book Value Per Share | 2.25 |
| Working Capital | 640.65M |
Cash Flow
In the last 12 months, operating cash flow was 120.65 million and capital expenditures -36.06 million, giving a free cash flow of 84.59 million.
| Operating Cash Flow | 120.65M |
| Capital Expenditures | -36.06M |
| Free Cash Flow | 84.59M |
| FCF Per Share | n/a |
Margins
Gross margin is 89.17%, with operating and profit margins of 28.29% and 34.78%.
| Gross Margin | 89.17% |
| Operating Margin | 28.29% |
| Pretax Margin | 27.67% |
| Profit Margin | 34.78% |
| EBITDA Margin | 29.18% |
| EBIT Margin | 28.29% |
| FCF Margin | 21.90% |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 0.11%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 0.11% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.62% |
| Buyback Yield | -0.44% |
| Shareholder Yield | -0.32% |
| Earnings Yield | 2.58% |
| FCF Yield | 1.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaEssentia has an Altman Z-Score of 26.07 and a Piotroski F-Score of 6.
| Altman Z-Score | 26.07 |
| Piotroski F-Score | 6 |